2026-05-22T00:53:39Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/234402024-11-28T20:17:15Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967

00925njm 22002777a 4500 dc Torrens-Mas, Margalida author Perelló-Reus, Catalina M author Trias-Ferrer, Neus author Ibargüen-González, Lesly author Crespí, Catalina author Galmes-Panades, Aina Maria author Navas-Enamorado, Cayetano author Sanchez-Polo, Andrés author Pierola Lopetegui, Javier author Masmiquel, Lluis author Socias, Lorenzo author Barceló, Carles author Gonzalez-Freire, Marta author 2022-07-22 Coronavirus disease 19 (COVID-19) is a persistent global pandemic with a very heterogeneous disease presentation ranging from a mild disease to dismal prognosis. Early detection of sensitivity and severity of COVID-19 is essential for the development of new treatments. In the present study, we measured the levels of circulating growth differentiation factor 15 (GDF15) and angiotensin-converting enzyme 2 (ACE2) in plasma of severity-stratified COVID-19 patients and uninfected control patients and characterized the in vitro effects and cohort frequency of ACE2 SNPs. Our results show that while circulating GDF15 and ACE2 stratify COVID-19 patients according to disease severity, ACE2 missense SNPs constitute a risk factor linked to infection susceptibility. Torrens-Mas M, Perelló-Reus CM, Trias-Ferrer N, Ibargüen- González L, Crespí C, Galmes-Panades AM, et al. GDF15 and ACE2 stratify COVID-19 patients according to severity while ACE2 mutations increase infection susceptibility. Front Cell Infect Microbiol. 2022 Jul 22;12:942951. 10.3389/fcimb.2022.942951 2235-2988 Frontiers in cellular and infection microbiology http://hdl.handle.net/20.500.13003/18040 35937703 L2018441801 2-s2.0-85135551051 https://hdl.handle.net/20.500.12105/23440 837144000001 GDF15 and ACE2 stratify COVID-19 patients according to severity while ACE2 mutations increase infection susceptibility